WO2023105417 - DANEGAPTIDE FORMULATION FOR APPLICATOIN IN THE EYE

National phase entry:
Publication Number WO/2023/105417
Publication Date 15.06.2023
International Application No. PCT/IB2022/061849
International Filing Date 06.12.2022
Title [English] DANEGAPTIDE FORMULATION FOR APPLICATOIN IN THE EYE [French] FORMULATION DE DANEGAPTIDE POUR APPLICATION DANS L'ŒIL
Applicants ** BREYE THERAPEUTICS APS Ved Hegnet 2 2930 Rungsted Kyst, DK
Inventors ** MOURITZEN, Ulrik Ved Hegnet 2 2960 Rungsted Kyst, DK
Priority Data 63/286,348  06.12.2021  US
front page image
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 1921
EPO Filing, Examination 10849
Japan Filing 556
South Korea Filing 577
USA Filing, Examination 4635
MasterCard Visa
Total: 18538
The term for entry into the National Phase has expired. This quotation is for informational purposes only.

Abstract [English] The present disclosure relates to a slow and extended release formulation of danegaptide. [French] La présente divulgation concerne une formulation à libération lente et prolongée de danegaptide.